Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Deloitte
Citi
Daiichi Sankyo
Farmers Insurance
Express Scripts
Queensland Health
Chubb
Dow
Novartis

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,485,180

« Back to Dashboard

Summary for Patent: 8,485,180
Title:Dry powder drug delivery system
Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.
Inventor(s): Smutney; Chad C. (Watertown, CT), Adamo; Benoit (Mount Kisco, NY), Polidoro; John M. (Coventry, CT), Kinsey; P. Spencer (Sandy Hook, CT), Overfield; Dennis (Fairfield, CT), Sahi; Carl R. (Coventry, CT), Billings; Christine (Danbury, CT), Marino; Mark T. (Danbury, CT)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:12/717,884
Patent Claim Types:
see list of patent claims
Formulation; Delivery;

Drugs Protected by US Patent 8,485,180

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-001 Jun 27, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-002 Jun 27, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-003 Apr 17, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,485,180

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,377,869 Method of preventing adverse effects by GLP-1 ➤ Sign Up
9,358,352 Dry powder drug delivery system and methods ➤ Sign Up
8,921,311 Method for treating hyperglycemia ➤ Sign Up
8,912,193 Dry powder inhaler and system for drug delivery ➤ Sign Up
9,192,675 Dry powder inhaler and system for drug delivery ➤ Sign Up
9,283,193 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents ➤ Sign Up
8,785,396 Method and composition for treating migraines ➤ Sign Up
7,799,344 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents ➤ Sign Up
9,066,881 Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces ➤ Sign Up
9,339,615 Dry powder inhaler and system for drug delivery ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,485,180

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 201540332 ➤ Sign Up
Taiwan I592178 ➤ Sign Up
Taiwan 201002378 ➤ Sign Up
Taiwan I528982 ➤ Sign Up
Taiwan 201036656 ➤ Sign Up
Slovenia 2379100 ➤ Sign Up
Singapore 10201507038V ➤ Sign Up
Singapore 10201507036T ➤ Sign Up
Russian Federation 2014152320 ➤ Sign Up
Russian Federation 2012146344 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
McKinsey
Julphar
Citi
Harvard Business School
Moodys
US Department of Justice
Baxter
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot